Francisco Caballero

Francisco Caballero is a seasoned professional with a distinguished background in biochemistry and a robust track record in both academia and the corporate sector. Holding a PhD in Biochemistry from the University of Barcelona, he accumulated fourteen-years of research experience at prestigious institutions including Harvard Medical School and MIT.

With a passion for entrepreneurship, Francisco has played pivotal roles in various ventures. He was actively involved in the creation of Sigilon Therapeutics (acquired by Eli Lilly in 2023), and co-founded Voltage Biopharma. Additionally, he founded CamBio LLC, a consulting company that has provided valuable insights to startups and pharmaceutical companies in the Boston Area. In his latest position at Danaher Corporation, he was involved in the first pioneer program of the company successfully launched (BlueWhale Bio).

Caballero's multifaceted career reflects his commitment to advancing scientific discovery, fostering innovation, and contributing to the success of both established and emerging enterprises in the biotechnology and pharmaceutical sectors.